Submit Deal

GENMAB AS

HQ - Copenhagen

Summary

Genmab is a biotechnology company that focuses on the development and commercialization of differentiated antibody therapeutics for the treatment of cancer.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 7.33 B

Avg. Deal Size£ 3.67 B

Market Context

Senior Management

Jan van de Winkel
President and CEO
Jan van de Wilken
President and CEO
Marisol Peron
Senior Vice President

Sort

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.43 B

Total Value

bank of america

HQ - Charlotte

financial advisors (1)

1 Shared Deal

1 Opposite

£ 1.43 B

Total Value

jun he law

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.43 B

Total Value

morgan stanley

HQ - New York

financial advisors (2)

2 Shared Deals

1 For | 1 Opposite

£ 7.33 B

Total Value

travers thorp alberga

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.43 B

Total Value

wilson sonsini goodrich & rosati

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.43 B

Total Value

shearman & sterling

HQ - New York

legal advisors (1)

1 Shared Deal

1 For

£ 1.43 B

Total Value

simmons & simmons

HQ - London

legal advisors (1)

1 Shared Deal

1 For

£ 1.43 B

Total Value

sullivan & cromwell

HQ - New York

legal advisors to financial advisors (1)

1 Shared Deal

1 For

£ 1.43 B

Total Value

goldman sachs

HQ - New York, United States

financial advisors (1)

1 Shared Deal

1 For

£ 1.43 B

Total Value

kromann reumert

HQ - Copenhagen, Denmark

legal advisors (2)

2 Shared Deals

2 For

£ 7.33 B

Total Value

ropes & gray

HQ - Boston

legal advisors to financial advisors (1)

1 Shared Deal

1 Opposite

£ 5.90 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy